

MARKING CRITERIA

A. Technical (80 Marks)				
Sr. No.	Parameters	Details	Maximum grade	Remarks
1.	Product Registration	Category -A 1) US FDA 2) EMA (Europe source only) 3) MHRA UK 4) TGA Australia 5) PHARMAC. New Zealand 6) PMDA Japan 7) Swiss-Medics Switzerland 45 8). Health Canada 9) HAS Singapore	45	
		Category -B 1) ANVIZ Brazil 2) CDSCO India 3) NPCB Malaysia 4) FDA South Korea 40 5). MOH Egypt 6) MOH Turkey 7) FDA China 8). ANMAT Argentina 9). DRA Pakistan 35 10). any other Authorities not mentioned in category-A	35	
2.	Bio-availability/Bio equivalence/ Bio similar certificate.	Whatever and wherever applicable	10	10 marks will be given in case where none is applicable for certain formula
3.	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted item is drug. In case if the quoted item is generic the studies must be performed on the generic and not on the originator. (Must be an original research article).	In case the study is published in journal listed in HEC Journal Recognition System (HJRS) Database.	5 (Only if study is provided in CD.)	DOI or article title page copy is mandatory to provide (both in soft and hard form) and mentioned in format form.
		In case the study is published in journal NOT listed in HEC Journal Recognition System (HJRS) Database	0	
4.	Cold Chain Facility	Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP. PSQCA, and PCSIR	5	The procurement entity reserves the right to visit any cold chain facility for physical Inspection/ verification
		NON-Compliance to international reference standards or absence of cold chain requirement	0	Disqualification

Marking Criteria

MARKING CRITERIA

5.	Current GMP Certificate	Issued by authorities as mentioned in Category A as mentioned above in Sr. no. 1	5	Certificate should be attached with technical bid
		Issued by authorities as mentioned in Category B as mentioned above in Sr. no. 1	2	
6.	Past Performance (Last two years)	- Agha Khan University Hospital Karachi. - Shaukat Khanum Hospitals - Shifa International hospital Islamabad. - Atomic Energy Cancer Hospitals	5	Invoice proof clearly showing date and quantity of supply and also "Good performance Certificate" will be needed from the institute to which the supplies are made.
		Others	2	

B. Financial (20 Marks)

7.	Financial status: (The price quoted must be the lowest quoted anywhere in Pakistan in the previous twelve months in case this is bound to refund the difference of the price to the procuring agency.)	(Lowest Bid/Your Bid) x 20
----	---	----------------------------

C. Supplier Marks (05)

8.	If Manufacturer or Importer submit bids	05
	If Manufacturer or Importer submit bids via Distributor	0

Total Technical score = 75

Qualifying marks in technical: 45

Total financial score = 20

Supplier Marks = 05

Total score: 100




General Secretary, BPWS

Marking Criteria



TENDER FOR ANTI-CANCER MEDICINE PURCHASE FOR BINOR PATIENTS WELFARE SOCIETY (BPWS), PHARMACY.

Eligibility Criteria

01. All importers, manufacturers, and distributors must hold the applicable licenses and approvals required by the relevant authorities.
02. All importers/manufacturers or distributors must be listed on the Active Taxpayers List (ATL) of FBR.

Terms & Conditions

03. The invitation for Bids is open for all eligible/qualified manufacturers importers or their authorized agents in Pakistan for supply of anti-cancer medicine as per the attached sheet on competitive bidding of **single stage two envelopes procedure basis**.
04. The price quoted must be the lowest quoted anywhere in Pakistan like quoted in MCC.
05. Bidders are advised to submit their bids according to **prescribe format** which can be received from BPWS pharmacy along with bid documents Bids received on different formats, may not be considered.
06. Quotation must be accompanied with call deposit/ earnest money amounting **PKRs.500,000/- in favor of BPWS**.
07. The validity of tender should be for a period of 12 months from the date of awarding tender, which is extendable on mutual consents.
08. Supplier shall provide necessary Cheque acknowledgement receipt of payment made to them through crossed Cheque.
09. Payment will made on monthly basis, the amount of monthly payment to a particular supplier would depend on the sale of medicine of that particular supplier and payment from SLIC.
10. The supplier/firm having bad reputation/black list with any government 'organization etc. may not apply at all and will not be entertained.
11. Income Tax/GST as per rules of Govt shall be deducted on all supply.
12. The competent authority reserved the right to accept or reject any quotation/tender or part thereof without assigning any reason in writing.
13. The supplier will have to submit authorized distribution certificate from the concerned pharmaceutical at the time of tender.



TENDER FOR ANTI-CANCER MEDICINE PURCHASE FOR BINOR PATIENTS WELFARE SOCIETY (BPWS), PHARMACY.

14. The final selection will be made on the total final marks (Technical+ Financial base).
15. All medicines supplied shell be subject to the inspection by inspection office of pharmacist of this organization.
16. The price of medicine must be quoted in unit cost i.e. **per tab per capsule or per injection**.
17. The supplier will be responsible to maintain the cold chain of the medicines if applicable for any quality compromise due to cold chain breakage the supplier will be responsible.
18. While supplying the medicines only those medicine will be supplied which have the maximum expiry date available in the market and not less than 06 months All short expiry medicines will be replaced with fresh stock.
19. The amount of call deposit/ earnest money will be forfeited in case the firm/supplier fail to supply the medicines as per our specification requirement or violating any Bid terms & conditions.
20. **Passing marks in technical evaluation are 45 out of 80**
21. Winning firm will be bond to supply medicine within 72 hours, contrary BPWS pharmacy will go to next option.
22. BPWS will rank medicine as per given marking criteria. (Technical + Financial).
23. Marks for clinical study/trial documentation shall be awarded only if the relevant documents are submitted on CD.
24. Pre-bid meeting will be held to clarify important points and answer any question from bidder on - **15/10/2026 (12:30pm)** at BINOR auditorium. Those who want to clarify any of their queries can attend the meeting.
25. Last date for submission of bids is within 15 Days of tender publication on PPRA.

Note: Manufacturer or importers are encouraged to submit bids directly, and as such will be awarded additional 05 marks.


General Secretary, BPWS





BINOR PATIENTS WELFARE SOCIETY

List of Generic Name

S.#	Generic Name	S.#	Generic Name
1	Alpelisib 150 mg	46	Erdafitinib 4 mg
2	Anastrozole 1 mg	47	Eribulin 1 mg/2mL
3	Apalutamide 60 mg	48	Erlotinib 150 mg
4	Atezolizumab 1200 mg	49	Erythropoietin 10000 IU
5	Axitinib 5 mg	50	Etoposide 100 mg
6	Azacitidine 100 mg	51	Exemestane 25 mg
7	Bendamustine 100 mg	52	Filgrastim 300 µg
8	Bevacizumab 100 mg	53	Fludarabine 50 mg
9	Bevacizumab 400 mg	54	Fluorouracil (5-FU, 5-fluorouracil) 250 mg
10	Bicalutamide 50 mg	55	Fluorouracil (5-FU, 5-fluorouracil) 500 mg
11	Bleomycin 15 IU	56	Fulvestrant 250 mg
12	Bortezomib 3.5 mg	57	Gemcitabine 1000 mg
13	Cabazitaxel 60 mg	58	Gemcitabine 200 mg
14	Cabozantinib 20 mg	59	Goserelin 3.6 mg
15	Cabozantinib 80 mg	60	Hydroxyurea 500 mg
16	Capecitabine 500 mg	61	Ibrutinib 140 mg
17	Capmatinib 40 mg	62	Ifosfamide 1000 mg
18	Carboplatin 150 mg	63	Ifosfamide 2000 mg
19	Carboplatin 450 mg	64	Imatinib 100 mg
20	Cisplatin 10 mg	65	Imatinib 400 mg
21	Cisplatin 25 mg	66	Ipilimumab 50 mg
22	Cisplatin 50 mg	67	Irinotecan 100 mg
23	Crizotinib 250 mg	68	Irinotecan 300 mg
24	Cyclophosphamide (CP) 1000 mg	69	Irinotecan 40 mg
25	Cyclophosphamide (CP) 500 mg	70	Ivosidenib 250 mg
26	Cytarabine (ara-C) 100 mg	71	Lapatinib (INN) 250 mg
27	Cytarabine (ara-C) 1000 mg	72	Larotrectinib 100 mg
28	Cytarabine (ara-C) 500 mg	73	L-Asparaginase 10000 IU
29	Dacarbazine 200 mg	74	Lenalidomide 10 mg
30	Dacomitinib 45 mg	75	Lenalidomide 25 mg
31	Dactinomycin	76	Lenalidomide 5 mg
32	Daunorubicin 20 mg	77	Lenvatinib 10 mg
33	Denosumab 120 mg	78	Lenvatinib 4 mg
34	Docetaxel (DTX or DXL) 120 mg	79	Letrozole 2.5 mg
35	Docetaxel (DTX or DXL) 20 mg	80	Leucovorin Calcium (Folinic acid) 100 mg
36	Docetaxel (DTX or DXL) 80 mg	81	Leucovorin Calcium (Folinic acid) 15 mg
37	Doxorubicin 10 mg	82	Leucovorin Calcium (Folinic acid) 50 mg
38	Doxorubicin 50 mg	83	Leuprorelin (Leuprolide) 11.25 mg
39	Durvalumab 500 mg	84	Leuprorelin (Leuprolide) 3.75 mg
40	Eltrombopag 25 mg	85	Leuprorelin (Leuprolide) 7.5 mg
41	Eltrombopag 50 mg	86	Liposomal Doxorubicin 20 mg
42	Enasidenib 50 mg	87	Lorlatinib 100 mg
43	Enzalutamide 80 mg	88	Mercaptopurine (6-MP) 50 mg
44	Epirubicin 10 mg	89	Methotrexate (Amethopterin) 10 mg
45	Epirubicin 50 mg	90	Methotrexate (Amethopterin) 1000 mg

BINOR PATIENTS WELFARE SOCIETY

List of Generic Name

S.#	Generic Name	S.#	Generic Name
91	Methotrexate (Amethopterin) 2.5 mg	133	Rituximab 100 mg
92	Methotrexate (Amethopterin) 50 mg	134	Rituximab 1400 mg
93	Methotrexate (Amethopterin) 500 mg	135	Rituximab 500 mg
94	Mitomycin 10 mg	136	Ruxolitinib 15 mg
95	Mobocertinib 40 mg	137	Ruxolitinib 5 mg
96	Nab-paclitaxel 100 mg	138	Sacituzumab govitecan 180 mg
97	Neratinib (INN)	139	Selinexor 20 mg
98	Nilotinib 150 mg	140	Selpercatinib 40 mg
99	Nilotinib 200 mg	141	Sodium2-Mercaptoethanesulfonate 100 mg
100	Niraparib 100 mg	142	Sorafenib 200 mg
101	Nivolumab 10 mg	143	Sotorasib 120 mg
102	Nivolumab 100 mg	144	Sunitinib 12.5 mg
103	Nivolumab 40 mg	145	Sunitinib 25 mg
104	Obinutuzumab 1000 mg	146	Sunitinib 50 mg
105	octreotide acetate	147	Talazoparib 1 mg
106	Olaparib 150 mg	148	Tamoxifen 10 mg
107	Oprelvekin(Recombinant Interleukin Eleven (IL-11)) 1.5 mg	149	Tamoxifen 20 mg
108	Osimertinib 80 mg	150	Temozolomide 100 mg
109	Oxaliplatin 100 mg	151	Temozolomide 20 mg
110	Oxaliplatin 50 mg	152	Temozolomide 250 mg
111	Paclitaxel 100 mg	153	Thalidomide 100 mg
112	Paclitaxel 150 mg	154	Tivozanib 1.34
113	Paclitaxel 30 mg	155	Topotecan 4 mg
114	Paclitaxel 300 mg	156	Trastuzumab 440 mg
115	Palbociclib 100 mg	157	Trastuzumab 600 mg S/C
116	Palbociclib 125 mg	158	Trastuzumab deruxtecan 100 mg
117	Palbociclib 75 mg	159	Trifluridine/tipiracil (FTD-TPI) 15 mg
118	Pazopanib 200 mg	160	Tucatinib 150 mg
119	Pazopanib 400 mg	161	Venetoclax 10 mg
120	Pegaspargase	162	Vinblastine 10 mg
121	Pegfilgrastim 6 mg	163	Vincristine 1 mg
122	Pegliposomal Doxorubicin 20 mg	164	Vincristine 2 mg
123	Pembrolizumab 100 mg	165	Vinorelbine 50 mg
124	Pemetrexed 100 mg	166	Zoledronic acid 4 mg
125	Pemetrexed 500 mg		
126	Pertuzumab 420 mg		
127	Pertuzumab/Trastuzumab 600 mg		
128	Polatuzumab vedotin 140 mg		
129	Ponatinib 15 mg		
130	Ponatinib 45 mg		
131	Ramucirumab 100 mg		
132	Regorafenib 40 mg		

BINOR PATIENTS WELFARE SOCIETY
Format For Financial Documents

[illegible]